Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer by Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer

Get full text

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours by J. Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y. Chung, Judy Wang, Gerald Falchook, James M. Cleary, Richard Kim, Anuradha Krishnamurthy, Omkar Marathe, Hagop Youssoufian, Catherine Ellis, Angela Waszak, Srimoyee Ghosh, Hailei Zhang, Kaitlin Yablonski, Shruti D. Shah, Ivan Diaz-Padilla, Susanna Ulahannan

Get full text

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols by Deborah Collyar, Christian M Capitini, Gary Kohanbash, Yana G Najjar, Carlo B Bifulco, Barbara Seliger, Holden T Maecker, Elizabeth Garrett-Mayer, Joe Yeong, Leslie Cope, Sacha Gnjatic, Sumit K Subudhi, Michael T Lotze, Saman Maleki Vareki, Alaa Ali, Laura Q M Chow, Tricia R Cottrell, Tullia C Bruno, Denise Goh, Codruta Chiuzan, Janis Taube, Ryan J Sullivan, Kristin G Anderson, Isabella C Glitza Oliva, Wim Vos, Paola Grandi, Susan Halabi, Julie Stein Deutsch, Ivan Diaz-Padilla, Anthony R Cillo, Genia Dubrovsky, Sarah Mullin, Elizabeth G Hill, Brian P Hobbs, Phyllis Pettit Nassi, Virgil H Simons, Chris H Takimoto

Get full text